Exploratory Study on the Effects of FE 999302 During Controlled Ovarian Stimulation with Follitropin Delta in Women Undergoing ART for Infertility

The primary objective of this study is to explore the effect of **FE 999302** when administered during different time periods to women undergoing controlled ovarian stimulation with **follitropin delta**. This investigation is clinically relevant as it aims to optimize treatment protocols for women experiencing **infertility** and undergoing assisted reproductive technologies (ART), potentially improving outcomes in this patient population.

The clinical trial focuses on **infertility in women undergoing assisted reproductive technologies (ART)**. The study population consists exclusively of female participants, as male subjects are not included. The age range of the participants falls within the category code "3," which typically corresponds to adults. The trial does not involve a vulnerable population. The sponsor has not provided information regarding the total number of participants or specific lifestyle considerations such as diet, physical activity, or habits. Additionally, key inclusion or exclusion criteria have not been disclosed by the sponsor.

The clinical trial is designed to explore the effects of **FE 999302** on women undergoing controlled ovarian stimulation as part of assisted reproductive technologies (ART) for **infertility**. This study is categorized as a Phase 3 trial and is expected to follow a randomized, double-blind, controlled design to ensure the reliability and validity of the results. The trial is scheduled to commence recruitment on July 20, 2024, and is anticipated to conclude by July 13, 2026, marking the overall trial duration.

Participants will undergo a series of study visits, beginning with an inclusion visit, also known as the screening visit, to assess eligibility based on predefined criteria. Following successful inclusion, participants will attend multiple follow-up visits, which are structured to monitor the effects of the intervention and ensure participant safety. These visits will include assessments of ovarian response and any potential side effects. The end-of-study visit will serve to collect final data and evaluate the overall outcomes of the treatment.

The expected length of participant involvement will span the duration of the treatment cycle, with specific timelines determined by the individual response to the intervention. Conditions that may lead to early termination from the study include adverse reactions to the treatment, non-compliance with study protocols, or withdrawal of consent by the participant. The study aims to provide valuable insights into the timing and efficacy of FE 999302 in enhancing the outcomes of ART in women facing infertility challenges.

No specific information regarding the experimental medication, including its name, pharmaceutical form, dosage, route, and frequency of administration, is provided in the available data. Consequently, a detailed description of the experimental treatment cannot be formulated based on the current dataset.

Similarly, there is no information available about any non-experimental treatments, such as standard-of-care therapy, placebo, or comparator treatment, used in the study. Therefore, a description of these elements cannot be provided.

Additional relevant information about drug administration, dosing schedules, and participant compliance monitoring is also absent from the provided data. As such, no further details can be included in this description.

The clinical trial is designed to assess efficacy in a Phase 3 study. The trial is scheduled to commence recruitment on July 20, 2024, with an estimated completion date of July 13, 2026. The efficacy assessment will be conducted through a series of predefined parameters, although specific endpoints are not detailed in the available data. The trial will follow a structured methodology to ensure the collection and analysis of efficacy data is consistent with clinical trial standards. The study will adhere to a rigorous schedule for measuring and collecting data, although specific timepoints and tools for efficacy assessments are not provided. The trial's design and execution will align with the regulatory requirements for Phase 3 studies, focusing on the evaluation of treatment efficacy in the target population.